CRL-40,940

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
CRL-40,940
CRL-40,940.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H13F2NO2S
Molar mass309.33 g/mol g·mol−1
3D model (JSmol)

CRL-40,940 (also known as flmodafinil, bisfluoromodafinil and lauflumide) is the bisfluoro analog of modafinil.[1][2][3][4] It is a eugeroic as well as a weak dopamine reuptake inhibitor. Its inventors claim that it is more effective than modafinil and adrafinil, with fewer side effects. It was patented in 2013, and Phase I clinical trials have been underway since December 2015.[5][6][7]

See also[edit]

References[edit]

  1. ^ Louis Lafon (28 January 1986). "Patent CA 1199916 A1 - Benzhydrylsulfinylacetamide derivatives". Retrieved 25 July 2015.
  2. ^ Jianjing Cao; Thomas E. Prisinzano; Oluyomi M. Okunola; Theresa Kopajtic; Matthew Shook; Jonathan L. Katz; Amy Hauck Newman (January 2011). "SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues". ACS Medicinal Chemistry Letters. 2 (1): 48–52. doi:10.1021/ml1002025. PMC 3041981. PMID 21344069.
  3. ^ Eric Konofal (7 November 2013). "Patent US 20130295196 A1 - Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof". Retrieved 25 July 2015.
  4. ^ Louis Lafon (18 December 1984). "Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids". Retrieved 25 July 2015.
  5. ^ http://nlspharma.com/science/pipeline/
  6. ^ http://adisinsight.springer.com/drugs/800043932
  7. ^ http://www.google.com/patents/US20130295196